Marsal JR, Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernandez-Felix BM, Oristrell G, Rodenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-Gonzalez I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights. Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4
DiSantostefano RL, Sutphin J, Hedrick JA, Klein K, Mansfield C. Parent preferences for delaying insulin dependence in children at risk of Stage III Type 1 Diabetes. Diabetes Technol Ther. 2020 Mar 11. doi: 10.1089/dia.2019.0444.
Gabbay RA, McGinley (Miller) EL. Editorial - The Affordable Care Act, technology, and type 1 diabetes mellitus. Diabetes Technol Ther. 2014 Dec;16(12):819-21. doi: 10.1089/dia.2014.0258
Glück S, Russell C, O'Shaughnessy J, McKenna EF, Hu S, Odom D, Blum JL. Treatment effect of capecitabine and docetaxel or docetaxel alone by oestrogen receptor status in patients with metastatic breast cancer: results of an exploratory analysis. Breast. 2013 Dec;22(6):1087-93. doi: 10.1016/j.breast.2013.08.016.
Bartha E, Davidson T, Brodtkorb T, Carlsson P, Kalman S. Value of information: interim analysis of a randomized, controlled trial of goal-directed hemodynamic treatment for aged patients. Trials. 2013 Jul 9;14:205.